Vertex Pharmaceuticals/$VRTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Ticker

$VRTX
Sector
Primary listing

Employees

6,100

VRTX Metrics

BasicAdvanced
$105B
29.16
$14.07
0.44
-

What the Analysts think about VRTX

Analyst ratings (Buy, Hold, Sell) for Vertex Pharmaceuticals stock.

Bulls say / Bears say

The European Union granted approval for Vertex’s next-generation CFTR modulator Alyftrek in July 2025, expanding its addressable cystic fibrosis population across major EU markets and strengthening its CF leadership ahead of Trikafta’s 2037 patent expiry (Reuters).
Vertex topped Q2 2025 estimates with 12% revenue growth to $2.96 billion and adjusted EPS of $4.52, driven by robust demand for its CF franchise and recent launches (Reuters).
The newly launched non-opioid pain therapy Journavx has rapidly gained commercial traction, with nearly 80,000 prescriptions filled since its March debut, demonstrating strong early market adoption (Reuters).
Vertex missed first-quarter 2025 Wall Street expectations, reporting $2.77 billion in revenue versus the $2.85 billion forecast largely due to underwhelming Trikafta sales of $2.53 billion (versus $2.58 billion est.), dragging adjusted EPS to $4.06 versus $4.32 expected (Reuters).
The company halted development of its experimental non-opioid painkiller after a mid-stage trial failed to meet statistical efficacy endpoints, triggering an 11% share sell-off despite overall Q2 beats and highlighting pipeline execution risks (Reuters).
Although JourNavx has achieved 79,763 prescriptions since its early 2025 launch, analysts caution that this uptake remains below internal targets and may limit the therapy’s near-term revenue contribution (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.

VRTX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

VRTX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VRTX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs